Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome
ConclusionsIn addition to beneficial effects of DJBL on weight loss, glycaemic control and lipid parameters in patients with MS, this is the first study that could further reveal significant impact on serological cardiovascular biomarkers and estimated CV risk, suggesting putative protective effects of DJBL on CV outcome.
Source: Obesity Surgery - Category: Surgery Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Metabolic Syndrome | Obesity | Study | Sugar | Surgery | Weight Loss